Vera Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results
Vera Therapeutics announced that the FDA granted Priority Review to the BLA for atacicept for the treatment of IgA Nephropathy, with a target PDUFA action date of July 7, 2026. The company is on track for a potential U.S. commercial launch of atacicept in mid-2026, pending regulatory approval, and reported a strong balance sheet with nearly $597M in cash and equivalents to fund operations beyond launch.
Key figures
- Rd expenses
- 86011000
- Cash position
- 596760000
- G and a expenses
- 39121000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.